Home Colorectal Cancer CRC screening, gastric cancer rates

CRC screening, gastric cancer rates

38
0

August 21, 2020

1 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

A recent report found that most patients who refuse to participate in fecal immunochemical tests or colonoscopy screening prefer the Epi proColon blood test for colorectal cancer screening. It was the top story in gastroenterology last week.

Another top story was about a study that revealed high rates of gastric cancer among certain racial and ethnic groups aged 50 years and older.

Photo of blood test tubes

A study in the Journal of the National Cancer Institute concludes that Epi proColon is the test of choice for individuals not willing to participate in fecal immunochemical tests or colonoscopy screening. Photo source: Adobe Stock.

Read these and more top stories in gastroenterology below:

Q&A: Patients who refuse FIT, colonoscopy prefer blood test for CRC screening

A study published in the Journal of the National Cancer Institute concludes that Epi proColon is the test of choice for individuals not willing to participate in fecal immunochemical tests or colonoscopy screening. Read more.

Gastric cancer rates high among certain ethnic groups aged 50 years or older

Investigators found differences in the incidence of gastric adenocarcinoma in specific anatomic sites among certain racial and ethnic groups aged 50 years and older, according to results published in Gastroenterology. Read more.

ACG issues guidelines for esophageal physiologic tests

The American College of Gastroenterology developed new clinical guidelines for esophageal physiologic tests. The recommendations were published in the American Journal of Gastroenterology. Read more.

Childhood celiac linked with increased risk for psychiatric disorders

Patients diagnosed with celiac disease in childhood have a higher risk for psychiatric disorders, with the increased risk persisting until adulthood, according to study results. Read more.

Stelara shows efficacy in real-world study

After 52 weeks of treatment, Stelara (ustekinumab, Janssen) helped induce clinical and endoscopic remission in patients with refractory Crohn’s disease, according to study results. Read more.

https://www.healio.com/news/primary-care/20200820/top-in-gi-crc-screening-gastric-cancer-rates

This site uses Akismet to reduce spam. Learn how your comment data is processed.